GlassScriptPhysician profile
Thomas Carter Towne
NPI 1700888385
$10,679.66
in general payments reported to CMS, 2019-2025
34 companies · $15.21 in 2025
The $15.21 reported for 2025 was less than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,016 · 2020: $365 · 2021: $414 · 2022: $2,681 · 2023: $2,260 · 2024: $2,928 · 2025: $15.21.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,577 · Consulting Fee: $1,562 · Education: $64.61.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,577.21 |
| Consulting Fee | $1,561.50 |
| Education | $64.61 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $2,058.08 | 2019-2024 | Rinvoq, Skyrizi, Linzess |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $1,784.01 | 2019-2025 | Xifaxan, Trulance, Plenvu |
| Fujifilm Healthcare Americas Corporation | $1,561.50 | 2024 | Fujifilm |
| Takeda Pharmaceuticals U.S.A., INC. | $757.52 | 2019-2024 | Entyvio |
| Intercept Pharmaceuticals, INC. | $575.87 | 2019-2024 | Ocaliva |
| Janssen Biotech, INC. | $552.76 | 2019-2024 | Stelara, Simponi, Remicade |
| Celgene Corporation | $477.17 | 2022-2024 | Zeposia |
| Pfizer INC. | $367.70 | 2019-2024 | |
| Ferring Pharmaceuticals INC. | $292.48 | 2019-2023 | Rebyota |
| Merck Sharp & Dohme LLC | $244.32 | 2019-2024 | Dificid |
| Lilly USA, LLC | $221.74 | 2023-2024 | Omvoh |
| Ironwood Pharmaceuticals, INC | $206.30 | 2019-2024 | Linzess |
| Phathom Pharmaceuticals, INC. | $199.33 | 2024 | Voquezna |
| Genzyme Corporation | $191.43 | 2022-2024 | |
| Nestle Healthcare Nutrition INC. | $147.20 | 2021-2023 |
Show all 34 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Qol Medical, LLC | $141.00 | 2021-2022 | |
| Janssen Scientific Affairs, LLC | $130.78 | 2022 | |
| Boston Scientific Corporation | $119.23 | 2019-2024 | |
| Medical Device Business Services, INC. | $114.84 | 2019 | |
| Ardelyx, INC. | $67.37 | 2023-2024 | Ibsrela |
| Celltrion USA INC. | $64.61 | 2024 | Zymfentra |
| Regeneron Healthcare Solutions, INC. | $64.37 | 2022-2024 | Dupixent |
| Amag Pharmaceuticals, INC. | $63.99 | 2019-2022 | |
| Shield Therapeutics INC | $61.12 | 2023 | Accrufer |
| Evoke Pharma, INC. | $56.44 | 2021-2023 | Gimoti |
| Gilead Sciences, INC. | $35.42 | 2023-2024 | |
| Amgen INC. | $25.40 | 2022-2023 | Avsola, Amjevita |
| Aimmune Therapeutics, INC. | $17.10 | 2024 | |
| Ipsen Biopharmaceuticals, INC | $15.92 | 2024 | |
| Mallinckrodt Hospital Products INC. | $15.20 | 2023 | Terlivaz |
| Redhill Biopharma INC. | $13.65 | 2022 | |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $12.89 | 2019 | |
| Shire North American Group INC | $11.87 | 2019 | |
| Daiichi Sankyo INC. | $11.05 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Thomas Towne listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.